Overview Latest Regional Industry Featured Multimedia Other Languages Public Company News
CSL Vifor and Travere Therapeutics Announce European Commission approves FILSPARI® (sparsentan) for the treatment of IgA Nephropathy 2024-04-24 15:00
CSL Vifor and Travere Therapeutics announce sparsentan receives positive CHMP opinion for the treatment of IgA nephropathy 2024-02-23 15:00
1